Methodological Considerations Treatment Trials for Persons Personality Disorder

Overview

Journal Ann Clin Psychiatry

Specialty Psychiatry

Date 2010 May 7

PMID 20445834

Citations 11

Authors

Mary C Zanarini

Barbara Stanley

Donald W Black

John C Markowitz

Marianne Goodman

Paul Pilkonis

Thomas R Lynch

Kenneth Levy

Peter Fonagy

Martin Bohus

Joan Farrell

Charles Sanislow

Affiliations

Soon will be listed here.

Abstract

Background: The National Institute of Mental Health convened an international group of experts to examine the conduct of treatment trials for persons with borderline personality disorder (BPD). The rapid growth of treatment research had led to the recognition that investigators face unique methodological issues with these challenging patients.

Methods: Conference members reviewed critical aspects of psychotherapy and pharmacotherapy trial design for patients with BPD.

Results: This article summarizes discussions held on March 17-18, 2005.

Conclusion: This paper addresses the most pressing issues in sample selection and trial design pertaining to BPD; issues that have bedeviled both investigators submitting applications and reviewers trying to assess the merit of these grants. By disseminating this work, conference members hope to make this process more consistent and productive for all concerned.

Citing Articles

Which psychotherapy is most effective and acceptable in the treatment of adults with a (sub)clinical borderline personality disorder? A systematic review and network meta-analysis.

Setkowski K, Palantza C, van Ballegooijen W, Gilissen R, Oud M, Cristea I Psychol Med. 2023; 53(8):3261-3280.

PMID: 37203447 PMC: 10277776. DOI: 10.1017/S0033291723000685.

Mental Health in Childhood and Adolescence: The Role of Polyunsaturated Fatty Acids.

Bozzatello P, Blua C, Rocca P, Bellino S Biomedicines. 2021; 9(8).

PMID: 34440053 PMC: 8389598. DOI: 10.3390/biomedicines9080850.

High-dose antipsychotic drug use as a predictor for readmission of inpatients with borderline personality disorder: A retrospective chart review in a Japanese psychiatric hospital.

Yamada Y, Yokoi Y, Narita Z, Hirabayashi N Neuropsychopharmacol Rep. 2020; 40(4):365-370.

PMID: 33037872 PMC: 7722642. DOI: 10.1002/npr2.12140.

Specialized psychotherapies for adults with borderline personality disorder: A systematic review and meta-analysis.

Oud M, Arntz A, Hermens M, Verhoef R, Kendall T Aust N Z J Psychiatry. 2018; 52(10):949-961.

PMID: 30091375 PMC: 6151959. DOI: 10.1177/0004867418791257.

Consistency and coherence in treatment outcome measures for borderline personality disorder.

Madan A, Fowler J Borderline Personal Disord Emot Dysregul. 2015; 2:1.

PMID: 26401304 PMC: 4579515. DOI: 10.1186/s40479-014-0022-5.

References

Salzman C, Wolfson A, Schatzberg A, Looper J, Henke R, Albanese M . Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995; 15(1):23-9. DOI: 10.1097/00004714-199502000-00005. View

Zanarini M, Frankenburg F . Attainment and maintenance of reliability of axis I and II disorders over the course of a longitudinal study. Compr Psychiatry. 2001; 42(5):369-74. DOI: 10.1053/comp.2001.24556. View

Hollander E, Swann A, Coccaro E, Jiang P, Smith T . Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005; 162(3):621-4. DOI: 10.1176/appi.ajp.162.3.621. View

Loew T, Nickel M, Muehlbacher M, Kaplan P, Nickel C, Kettler C . Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006; 26(1):61-6. DOI: 10.1097/01.jcp.0000195113.61291.48. View

Bender D, Dolan R, Skodol A, Sanislow C, Dyck I, McGlashan T . Treatment utilization by patients with personality disorders. Am J Psychiatry. 2001; 158(2):295-302. DOI: 10.1176/appi.ajp.158.2.295. View

Giesen-Bloo J, van Dyck R, Spinhoven P, van Tilburg W, Dirksen C, van Asselt T . Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Arch Gen Psychiatry. 2006; 63(6):649-58. DOI: 10.1001/archpsyc.63.6.649. View

Clarkin J, Levy K, Lenzenweger M, Kernberg O . Evaluating three treatments for borderline personality disorder: a multiwave study. Am J Psychiatry. 2007; 164(6):922-8. DOI: 10.1176/ajp.2007.164.6.922. View

Baskin T, Tierney S, Minami T, Wampold B . Establishing specificity in psychotherapy: a meta-analysis of structural equivalence of placebo controls. J Consult Clin Psychol. 2003; 71(6):973-9. DOI: 10.1037/0022-006X.71.6.973. View

Linehan M, Schmidt 3rd H, Dimeff L, Craft J, Kanter J, Comtois K . Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict. 1999; 8(4):279-92. DOI: 10.1080/105504999305686. View

10.

Zanarini M, Frankenburg F, Dubo E, Sickel A, Trikha A, Levin A . Axis I comorbidity of borderline personality disorder. Am J Psychiatry. 1998; 155(12):1733-9. DOI: 10.1176/ajp.155.12.1733. View

11.

Zanarini M, Vujanovic A, Parachini E, Boulanger J, Frankenburg F, Hennen J . Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord. 2003; 17(3):233-42. DOI: 10.1521/pedi.17.3.233.22147. View

12.

Livesley W . A framework for integrating dimensional and categorical classifications of personality disorder. J Pers Disord. 2007; 21(2):199-224. DOI: 10.1521/pedi.2007.21.2.199. View

13.

Soler J, Pascual J, Campins J, Barrachina J, Puigdemont D, Alvarez E . Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005; 162(6):1221-4. DOI: 10.1176/appi.ajp.162.6.1221. View

14.

Davidson K, Norrie J, Tyrer P, Gumley A, Tata P, Murray H . The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. J Pers Disord. 2006; 20(5):450-65. PMC: 1852259. DOI: 10.1521/pedi.2006.20.5.450. View

15.

Zanarini M, Frankenburg F . omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2002; 160(1):167-9. DOI: 10.1176/appi.ajp.160.1.167. View

16.

Rinne T, van den Brink W, Wouters L, van Dyck R . SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002; 159(12):2048-54. DOI: 10.1176/appi.ajp.159.12.2048. View

17.

Gabbard G . Do all roads lead to Rome? New findings on borderline personality disorder. Am J Psychiatry. 2007; 164(6):853-5. DOI: 10.1176/ajp.2007.164.6.853. View

18.

Linehan M, Comtois K, Murray A, Brown M, Gallop R, Heard H . Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006; 63(7):757-66. DOI: 10.1001/archpsyc.63.7.757. View

19.

Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J . Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry. 2008; 165(4):468-78. PMC: 3608469. DOI: 10.1176/appi.ajp.2007.07071079. View

20.

Zimmerman M, Mattia J . Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry. 1999; 40(4):245-52. DOI: 10.1016/s0010-440x(99)90123-2. View